In the New York Times, Alex Berenson writes that blockbuster drugs are "so last century." Drug companies are starting to come to the realization that they do an "awful job of finding new medicines." Not only that -- "they rely too much on billion-dollar blockbuster drugs that are both overmarketed and overprescribed."

According to Big Pharma companies like Eli Lilly, the future is "not in blockbuster medicines like Prozac that are meant for tens of millions of patients, but rather in drugs that are aimed at smaller groups and can be developed more quickly and cheaply, possibly with fewer side effects." So will pharmaceutical companies based in New Jersey and New York, many of which have come to rely on the cash flows created by blockbuster drugs, also adapt their business models to the new reality?